Key Takeaways
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) faces a securities class-action lawsuit after its stock plunged over 70% following the U.S. Food and Drug Administration's rejection of its dry eye disease drug, reproxalap.
The FDA's Complete Response Letter stated there is "a lack of substantial evidence" and that the "inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings," according to the company's March 17 press release.
The news sent Aldeyra's stock down by $2.99, a 70.69% drop, to close at $1.24 per share. The lawsuit, filed on behalf of investors who purchased shares between November 3, 2023, and March 16, 2026, alleges the company made false statements about the drug's clinical trial consistency.
The rejection and subsequent lawsuit place the future of reproxalap in jeopardy, erasing hundreds of millions in market value. Investors now have until May 29, 2026, to file for lead plaintiff status in the case.
The complaint alleges that throughout the class period, Aldeyra failed to disclose that the clinical trial results for reproxalap were inconsistent and unreliable. Law firms including Bronstein, Gewirtz & Grossman and Pomerantz LLP contend that the company's repeated public statements describing the drug's trial data as showing "consistent statistically significant and clinically relevant activity" were materially false and misleading. The FDA's letter directly contradicted these claims, stating the "totality of evidence from the completed clinical trials does not support the effectiveness of the product."
The sharp stock decline highlights the risks for investors in biotechnology companies heavily dependent on regulatory approvals. The upcoming legal proceedings will scrutinize the company's disclosures and could result in significant damages if the allegations are proven.
This article is for informational purposes only and does not constitute investment advice.
